When a company such as SPDR Series Trust - S&P Pharmaceuticals ETF splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.

Looking at the XPH split history from start to finish, an original position size of 1000 shares would have turned into 2000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into SPDR Series Trust - S&P Pharmaceuticals ETF shares, starting with a $10,000 purchase of XPH, presented on a split-history-adjusted basis factoring in the complete XPH split history.

About SPDR Series Trust - S&P Pharmaceuticals ETF

SPDR S&P Pharmaceuticals is an open-end investment management company. The Fund seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. As of June 30 2015, the Fund's total assets and investment portfolio totaled $1,324,794,738 and $1,323,892,831, respectively. According to our XPH split history records, SPDR Series Trust - S&P Pharmaceuticals ETF has had 1 split.

XPH Split History | www.SplitHistory.com | Copyright © 2013 - 2024, All Rights Reserved